MCID: HMS001
MIFTS: 48

Hemosiderosis

Categories: Metabolic diseases, Rare diseases

Aliases & Classifications for Hemosiderosis

MalaCards integrated aliases for Hemosiderosis:

Name: Hemosiderosis 12 74 20 54 44 15 71
Haemosiderosis 12
Iron Overload 71

Classifications:



External Ids:

Disease Ontology 12 DOID:12119
MeSH 44 D006486
NCIt 50 C82892
SNOMED-CT 67 39011001
UMLS 71 C0019114 C0282193

Summaries for Hemosiderosis

Disease Ontology : 12 An iron metabolism disease that has material basis in an accumulation of hemosiderin, an iron-storage complex, resulting in iron overload.

MalaCards based summary : Hemosiderosis, also known as haemosiderosis, is related to pulmonary hemosiderosis and aceruloplasminemia. An important gene associated with Hemosiderosis is CP (Ceruloplasmin), and among its related pathways/superpathways are Insulin receptor recycling and Metal ion SLC transporters. The drugs Deferoxamine and Deferiprone have been mentioned in the context of this disorder. Affiliated tissues include liver, bone marrow and kidney, and related phenotypes are cellular and hematopoietic system

Wikipedia : 74 Hemosiderosis is a form of iron overload disorder resulting in the accumulation of... more...

Related Diseases for Hemosiderosis

Diseases related to Hemosiderosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 450)
# Related Disease Score Top Affiliating Genes
1 pulmonary hemosiderosis 32.8 PRTN3 MIF KRT7
2 aceruloplasminemia 30.9 TFR2 SLC40A1 SLC11A2 HJV HFE HAMP
3 atransferrinemia 30.5 TFR2 TF SLC40A1 SLC11A2 HJV HFE
4 hemoglobin h disease 30.1 TF HAMP EPO
5 respiratory failure 30.0 TF GPT EPO ALB
6 celiac disease 1 29.9 HP HFE GPT ALB
7 rare hereditary hemochromatosis 29.9 TFR2 TF SLC40A1 HJV HFE HAMP
8 siderosis 29.8 TF SLC40A1 HFE HAMP GPT CP
9 congenital dyserythropoietic anemia 29.8 HFE HAMP EPO
10 hypochromic microcytic anemia 29.7 TF SLC11A2 HJV HAMP CP
11 viral hepatitis 29.6 HFE GPT CP ALB
12 exanthem 29.6 PRTN3 GPT ALB
13 liver cirrhosis 29.5 TF HP HFE GPT CP ALB
14 beta-thalassemia 29.5 TFR2 TF HJV HFE HAMP GPT
15 liver disease 29.5 TF HFE GPT CP ALB
16 neutropenia 29.4 GPT EPO CP ALB
17 alcoholic liver cirrhosis 29.4 TF GPT ALB
18 iga glomerulonephritis 29.4 PRTN3 MIF ALB
19 pancytopenia 29.4 U2AF1 HP EPO CP
20 wilson disease 29.3 HP HFE GPT CP CAT
21 iron metabolism disease 29.3 TFR2 TF SLC40A1 SLC11A2 HJV HFE
22 miliary tuberculosis 29.3 EPO ALB
23 iron deficiency anemia 29.3 TFR2 TF SLC40A1 SLC11A2 HJV HFE
24 cholelithiasis 29.2 HP GPT ALB
25 alcohol use disorder 29.2 TF HFE GPT ALB
26 sideroblastic anemia 29.2 TFR2 SLC40A1 HFE HAMP
27 alpha-thalassemia 29.1 HP HFE HAMP EPPIN EPO
28 esophageal varix 29.1 HP GPT CP ALB
29 cerebellar disease 29.1 U2AF1 EPPIN CP
30 chronic kidney disease 29.0 TF HP HAMP EPO ALB
31 myelodysplastic syndrome 29.0 U2AF1 HFE HAMP EPO ALB
32 primary biliary cholangitis 28.9 PRTN3 KRT7 GPT CP ALB
33 anemia, sideroblastic, 1 28.9 TFR2 SLC40A1 SLC11A2 HJV HAMP
34 kidney disease 28.8 TF PRTN3 HP EPO ALB
35 acute kidney failure 28.8 PRTN3 HP GPT ALB
36 thrombocytopenia 28.7 U2AF1 HP GPT EPO ALB
37 cystic fibrosis 28.6 PRTN3 HP HFE CP ALB
38 microcytic anemia 28.4 TFR2 TF SLC40A1 SLC11A2 HJV HFE
39 hemoglobinopathy 28.2 TFR2 TF HP HJV HFE HAMP
40 diabetes mellitus 28.2 TF MIF HP HFE GPT EPO
41 porphyria 28.1 TFR2 SLC40A1 HJV HFE HAMP EPO
42 hemochromatosis, type 1 28.1 TFR2 TF SLC40A1 SLC11A2 HP HJV
43 porphyria cutanea tarda 27.9 TFR2 TF SLC40A1 HJV HFE HAMP
44 deficiency anemia 27.8 U2AF1 TFR2 TF SLC40A1 SLC11A2 HP
45 superficial siderosis 11.4
46 gracile syndrome 11.2
47 heiner syndrome 11.0
48 secondary pulmonary hemosiderosis 11.0
49 hemosiderosis, pulmonary, with deficiency of gamma-a globulin 10.9
50 thalassemia 10.4

Graphical network of the top 20 diseases related to Hemosiderosis:



Diseases related to Hemosiderosis

Symptoms & Phenotypes for Hemosiderosis

MGI Mouse Phenotypes related to Hemosiderosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.06 ALB CAT CP EPO HFE HP
2 hematopoietic system MP:0005397 10 CP EPO HFE HJV HP MIF
3 homeostasis/metabolism MP:0005376 9.97 ALB CAT CP EPO HFE HJV
4 immune system MP:0005387 9.73 ALB CP EPO HFE HJV HP
5 liver/biliary system MP:0005370 9.28 ALB CP EPO HFE HJV HP

Drugs & Therapeutics for Hemosiderosis

Drugs for Hemosiderosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
2
Deferiprone Approved Phase 4 30652-11-0 2972
3
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381 214348
4
Iron Approved Phase 4 7439-89-6 23925 29936
5
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
6
Trichostatin A Experimental Phase 4 58880-19-6
7 Pharmaceutical Solutions Phase 4
8 Antioxidants Phase 4
9 Trace Elements Phase 4
10 Vitamins Phase 4
11 Nutrients Phase 4
12 Micronutrients Phase 4
13 Protective Agents Phase 4
14 Chelating Agents Phase 4
15 Iron Chelating Agents Phase 4
16 Cyclosporins Phase 4
17 Immunosuppressive Agents Phase 4
18
Zinc Approved, Investigational Phase 3 7440-66-6 32051
19
Hydroxyurea Approved Phase 2, Phase 3 127-07-1 3657
20
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
21
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 209810-58-2, 11096-26-7
22
Amlodipine Approved Phase 3 88150-42-9 2162
23 Orange Approved Phase 3
24
tannic acid Approved Phase 3 1401-55-4
25
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
26 Zinc Supplement Phase 3
27 silymarin Phase 2, Phase 3
28 Omega 3 Fatty Acid Phase 2, Phase 3
29 Nigella Phase 2, Phase 3
30 Calcium, Dietary Phase 3
31 Ferric Oxide, Saccharated Phase 2, Phase 3
32 Epoetin alfa Phase 2, Phase 3 113427-24-0
33 Antihypertensive Agents Phase 3
34 Hormones Phase 3
35 Vasodilator Agents Phase 3
36 calcium channel blockers Phase 3
37
Calcium Nutraceutical Phase 3 7440-70-2 271
38
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054
39 Hepcidins Phase 2
40 Vitamin B 6 Phase 2
41 Anti-Infective Agents Phase 2
42
Pyridoxal Experimental, Nutraceutical Phase 2 66-72-8 1050
43
Nifedipine Approved Phase 1 21829-25-4 4485
44
Acetylcysteine Approved, Investigational Phase 1 616-91-1 12035
45
Cysteine Approved, Nutraceutical Phase 1 52-90-4 5862
46 Tocolytic Agents Phase 1
47 Respiratory System Agents Phase 1
48 Antiviral Agents Phase 1
49 Expectorants Phase 1
50 N-monoacetylcystine Phase 1

Interventional clinical trials:

(show top 50) (show all 175)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Unknown status NCT02041299 Phase 4 Deferiprone;Deferoxamine
2 A Single-arm, Open-label Study of the Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food Completed NCT00845871 Phase 4 deferasirox:
3 1-year Extension to CICL670A2402 an Open-label, Multi-center Trial of the Efficacy and Safety of Long-term Treatment With Deferasirox (10 to 20 mg/kg/Day) in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2- Year Duration) Completed NCT00171301 Phase 4 Deferasirox
4 Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia Completed NCT03591575 Phase 4 Deferiprone oral solution;Placebo
5 A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/d) in Patients Three to Six Months After Allogeneic Hematopoietic Cell Transplantation in Whom Iron Overload is Present Completed NCT00654589 Phase 4 Deferasirox
6 A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 in Patients Diagnosed With Low and INT-1 Risk Myelodysplastic Syndrome (MDS) and Transfusion-dependent Iron Overload Completed NCT00481143 Phase 4 ICL670/Deferasirox
7 A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets Completed NCT03372083 Phase 4 Deferasirox
8 Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload Completed NCT01335035 Phase 4 deferasirox
9 A Single Arm, Multicenter, Open Label Study of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia Completed NCT01546415 Phase 4 Desferasirox
10 Increased Survival and Reversion of Iron-Induced Cardiac Disease in Patients With Thalassemia Major Receiving Intensive Combined Chelation Therapy Completed NCT00800761 Phase 4 Deferoxamine and Deferiprone;Deferoxamine
11 A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation. Completed NCT01610297 Phase 4 ICL670
12 Safety of Deferasirox (ICL670) and Deferoxamine (Desferal or DFO) Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload Completed NCT00901199 Phase 4 Combo Chelation with Deferasirox (Exjade) and Desferal (DFO)
13 A Phase IV , Multicenter ,Open Label ,Non Comparative ,Investigator Initiated Study , Evaluating the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load Completed NCT00452660 Phase 4 Exjade
14 1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. Completed NCT01250951 Phase 4 Deferasirox
15 Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload Completed NCT00564941 Phase 4 deferasirox
16 An Epidemiological Study to Assess the Prevalence of Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) Completed NCT01736540 Phase 4
17 A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade® (Deferasirox) (The MILE Study) Completed NCT00673608 Phase 4 deferasirox
18 An Open Label, Multi-center, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients With Non-transfusion Dependent Thalassemia Completed NCT01709838 Phase 4 deferasirox
19 Randomized Trial Comparing the Relative Efficacy of Deferiprone to That of Deferoxamine in Removing Excess Cardiac Iron in Thalassemia Major Patients Completed NCT00105495 Phase 4 Ferriprox (deferiprone);Desferal (deferoxamine)
20 Effects of Ascorbic Acid Administration in the Treatment of Anemia in Chronic Hemodialysed Patients With Iron Overload Recruiting NCT02225886 Phase 4 Ascorbic Acid
21 Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Enrolling by invitation NCT02443545 Phase 4 Deferiprone
22 Open-label Study of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Undergoing Treatment Programs in Comparison With Control Group Terminated NCT01818726 Phase 4 ICL670;Chelation;No chelation
23 A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload. Terminated NCT01326845 Phase 4 Deferasirox
24 A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload Unknown status NCT01511848 Phase 2, Phase 3 DFP (ferriprox) and deferasirox (ICL 670);DFP, DFO
25 Effect of Mode of Delivery of Iron and/or Iron and Zinc Supplement on Iron Status Markers and Potential Markers of Iron Toxicity in Children Aged 24-36 Months Unknown status NCT00980421 Phase 3
26 Combined Therapy of Silymarin and Desferrioxamine in Patients With B-thalassemia Major: a Randomized Double-blind Clinical Trial Unknown status NCT00999349 Phase 2, Phase 3 Silymarin (LEGALON);Placebo
27 An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670)in β-thalassemia Patients With Transfusional Iron Overload Completed NCT00171210 Phase 3 Deferasirox
28 A 5-year Open Label, Non-comparative Extension to a Randomized, Open-label, Phase IIa Study to Evaluate Safety, Tolerability and the Effects on Liver Iron Concentration of Repeated Doses of 10 and 20 mg/kg/Day of Deferasirox in Comparison With 40 mg/kg/Day Deferoxamine in Patients With Transfusion-dependent Iron Overload Completed NCT01033747 Phase 2, Phase 3 Deferasirox;Deferasirox
29 Impact of Combination Therapy Between Hydroxy Urea, Omega 3, Nigella Sativa and Honey on Antioxidant-oxidant Status and Reduction of Iron Overload in Pediatric Major Thalassemia Completed NCT04292314 Phase 2, Phase 3 Omega 3;Nigella Sativa Oil;Hydroxyurea;Honey;Deferoxamine
30 A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis Completed NCT00061750 Phase 3 ICL670;deferoxamine
31 Open-label, Multicenter, Single Arm, Phase III Study to Collect Additional Safety and Efficacy Data With Deferasirox Film-coated Tablets in Patients Completing Study CICL670F2201 Completed NCT02720536 Phase 3 Deferasirox
32 A One Year, Open-label, Single-arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/Day) in Patients Diagnosed With Transfusion-dependent Iron Overload Completed NCT00171821 Phase 3 Deferasirox
33 Multicentre, Randomised, Open Label, Non-inferiority Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies Completed NCT01825512 Phase 3 Deferiprone;Deferasirox
34 A 24-Week, Open Label, Uncontrolled Study of the Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients With Transfusion-Dependent Anemia Completed NCT00529152 Phase 3 Deferiprone
35 Darbepoetin-alpha and i.v. Iron Administration After Autologous Hematopoietic Stem Cell Transplantation : a Prospective Randomized Trial Completed NCT00557817 Phase 2, Phase 3 Darbepoetin alpha (Aranesp);Iron saccharate (Venofer)
36 Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major: a Randomized, Controlled Trial Completed NCT01395199 Phase 3 Amlodipine
37 Prospective Randomized Study Comparing the Effect of Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only on Glycemia in Patients With Dysmetabolic Liversiderosis Completed NCT01045525 Phase 3
38 A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators Completed NCT00235391 Phase 3 Deferasirox
39 Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major Completed NCT01125254 Phase 2, Phase 3 Amlodipine
40 Efficacy and Safety of the Iron Chelator Deferiprone on Iron Overload in the Brain in Parkinson's Disease Completed NCT00943748 Phase 2, Phase 3 deferiprone;placebo
41 Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients Completed NCT00350662 Phase 3 Deferiprone (L1);Desferrioxamine
42 Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis. Completed NCT00469560 Phase 3 Deferasirox
43 A Study of Efficacy and Safety of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis Completed NCT00171171 Phase 3 deferasirox
44 Dose Escalating Study to Evaluate Pharmacokinetics, Efficacy and Safety of Apotransferrin in Atransferrinemia Patients Recruiting NCT01797055 Phase 2, Phase 3 Human apotransferrin
45 Clinical Importance of Treating Iron Overload in Sickle Cell Disease Terminated NCT00981370 Phase 3 deferasirox
46 Influence of Iron Depletion by Phlebotomy on the Risk of Hepatocellular Carcinoma Occurrence in Patients With Compensated Alcoholic Cirrhosis. Prospective, Multicentre, Randomized Trial Terminated NCT01342705 Phase 3
47 A Multi-Center, Randomized, Open-Label, Parallel Group Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia Unknown status NCT03381833 Phase 2 LJPC-401;LJPC-401
48 A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload Unknown status NCT01284946 Phase 2 Exjade
49 A Multicenter, Randomized, Open-label Phase II Trial Evaluating Deferasirox Compared With Deferoxamine in Patients With Cardiac Iron Overload Due to Chronic Blood Transfusions Completed NCT00600938 Phase 2 Core Study: Deferasirox;Core Study: Deferoxamine;Extension: deferoxamine to deferasirox;Extension: deferasirox to deferoxamine;Deferasirox;Deferoxamine
50 A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis Completed NCT00067080 Phase 2 ICL670, deferoxamine

Search NIH Clinical Center for Hemosiderosis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Cyclophosphamide
deferasirox
deferiprone

Cochrane evidence based reviews: hemosiderosis

Genetic Tests for Hemosiderosis

Anatomical Context for Hemosiderosis

MalaCards organs/tissues related to Hemosiderosis:

40
Liver, Bone Marrow, Kidney, Spleen, Pituitary, Pancreas, Endothelial

Publications for Hemosiderosis

Articles related to Hemosiderosis:

(show top 50) (show all 11396)
# Title Authors PMID Year
1
Severe hypochromic microcytic anemia in a patient with congenital atransferrinemia. 61 54
19579082 2009
2
Hematologic iron analyte values as an indicator of hepatic hemosiderosis in Callitrichidae. 54 61
18366107 2008
3
Study of the eye and lacrimal glands in experimental iron overload in rats in vivo. 54 61
18402083 2008
4
Metastatic carcinomatous cirrhosis and hepatic hemosiderosis in a patient heterozygous for the H63D genotype. 54 61
11473464 2001
5
Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. 61 54
10655270 2000
6
[A case of hereditary ceruloplasmin deficiency with hemosiderosis]. 54 61
10391079 1999
7
[Cerebral hemosiderosis related to hereditary ceruloplasmin deficiency. Clinical familial case study]. 61 54
9773037 1998
8
A novel splicing mutation in the ceruloplasmin gene responsible for hereditary ceruloplasmin deficiency with hemosiderosis. 54 61
9559983 1998
9
Hereditary ceruloplasmin deficiency with hemosiderosis. 54 61
8641692 1996
10
Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. 61 54
7755360 1995
11
A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. 61 54
7539672 1995
12
Management of hemosiderosis complicated by coexistent anemia with recombinant human erythropoietin and phlebotomy. 54 61
8362602 1993
13
The use of nuclear magnetic resonance imaging in monitoring total body iron in hemodialysis patients with hemosiderosis treated with erythropoietin and phlebotomy. 54 61
1585939 1992
14
Successful treatment of hemosiderosis with regular phlebotomy and recombinant human erythropoietin. Case report and ferrokinetic studies. 54 61
1805491 1991
15
Usefulness of biochemical screening of diabetic patients for hemochromatosis. 61 54
2351033 1990
16
Correction of serious iron overload in a chronic hemodialysis patient by recombinant human erythropoietin and removal of red blood cells: confirmation by follow-up liver biopsy. 61 54
2077417 1990
17
The association between pre-transfusion hemoglobin levels and thalassemia complications. 61
33357151 2021
18
Analysis of the influencing factors related to liver and cardiac iron overload in MDS patients detected by MRI in the real world. 61
33491605 2021
19
Biochemical effects of deferasirox and deferasirox-loaded nanomicellesin iron-intoxicated rats. 61
33545199 2021
20
Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). 61
33401150 2021
21
Sodium, Magnesium, Calcium, Manganese, Iron, Copper, and Zinc in Serums of Beta Thalassemia Major Patients. 61
32462603 2021
22
The Proteomics Study of Compounded HFE/TF/TfR2/HJV Genetic Variations in a Thai Family with Iron Overload, Chronic Anemia, and Motor Neuron Disorder. 61
32895881 2021
23
Iron Overload Resulting from the Chronic Oral Administration of Ferric Citrate Impairs Intestinal Immune and Barrier in Mice. 61
32468223 2021
24
The protective effect of the cardiac thioredoxin system on the heart in the case of iron overload in mice. 61
33370714 2021
25
Functional characterization of a novel SLC40A1 Arg88Ile mutation in a kindred with familial iron overload treated by phlebotomy. 61
33385755 2021
26
Splicing analysis of SLC40A1 missense variations and contribution to hemochromatosis type 4 phenotypes. 61
33341511 2021
27
Transfusion and Cellular Therapy in Pediatric Sickle Cell Disease. 61
33494879 2021
28
A disease-causing mutation K240E disrupts ferroportin trafficking by SUMO (ferroportin SUMOylation). 61
33490642 2021
29
Construction of an exposure-pathway-phenotype in children with depression due to transfusion-dependent thalassemia: Results of (un)supervised machine learning. 61
33445087 2021
30
Heme Oxygenase-1 Regulates Ferrous Iron and Foxo1 in Control of Hepatic Gluconeogenesis. 61
33408127 2021
31
Chondrocyte ferroptosis contribute to the progression of osteoarthritis. 61
33376672 2021
32
Aggressive corticosteroid treatment in childhood idiopathic pulmonary hemosiderosis with better outcome. 61
32505591 2021
33
Musculoskeletal imaging manifestations of beta-thalassemia. 61
33559685 2021
34
A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis. 61
33536631 2021
35
CD34-Positive Blast Count and p53 Expression in Bone Marrow Biopsies of Patients with Low-Risk Myelodysplastic Syndromes: Potential Predictive Tools of Response to Erythropoietin Stimulating Agents. 61
33588425 2021
36
People with blood disorders can be more vulnerable during COVID-19 pandemic: A hypothesis paper. 61
33608217 2021
37
Modulating NF-κB, MAPK, and PI3K/AKT signaling by ergothioneine attenuates iron overload-induced hepatocellular injury in rats. 61
33580994 2021
38
Effects of alpha lipoic acid on iron overload, lipid profile and oxidative stress indices in β-thalassemia major patients: A cross-over randomized controlled clinical trial. 61
33527721 2021
39
Clinical conundrum: managing iron overload after renal transplantation. 61
33547097 2021
40
Deferasirox-associated Fanconi syndrome in adult patients with transfusional iron overload. 61
33529394 2021
41
Iron derived from autophagy-mediated ferritin degradation induces cardiomyocyte death and heart failure in mice. 61
33526170 2021
42
Quantification of pancreatic iron overload and fat infiltration and their correlation with glucose disturbance in pediatric thalassemia major patients. 61
33532266 2021
43
The Perfect Balance? Managing Heavy Menstrual Bleeding and Dysmenorrhea in a Patient with Hereditary Hemochromatosis and von Willebrand Disease. 61
33096228 2021
44
How do I…perform therapeutic phlebotomy? 61
33580971 2021
45
Left ventricular deformation mechanics over time in patients with thalassemia major with and without iron overload. 61
33563223 2021
46
Activation of TRPC (Transient Receptor Potential Canonical) Channel Currents in Iron Overloaded Cardiac Myocytes. 61
33417472 2021
47
Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model. 61
33180328 2021
48
Sofosbuvir/Ledipasvir for Treatment of Chronic Hepatitis C Infection in Adult Patients with β- Thalassemia Major: A Real-Life Study. 61
33530921 2021
49
Aspects regarding renal morphophysiology of fruit-eating and vampire bats. 61
33232886 2021
50
Siderophores for medical applications: Imaging, sensors, and therapeutics. 61
33540031 2021

Variations for Hemosiderosis

Expression for Hemosiderosis

Search GEO for disease gene expression data for Hemosiderosis.

Pathways for Hemosiderosis

GO Terms for Hemosiderosis

Cellular components related to Hemosiderosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.02 TF PRTN3 MIF KRT7 HP GPT
2 extracellular region GO:0005576 9.96 TF PRTN3 MIF HP HAMP EPPIN
3 cell surface GO:0009986 9.8 TF SLC11A2 MIF EPPIN EPO
4 blood microparticle GO:0072562 9.62 TF HP CP ALB
5 secretory granule lumen GO:0034774 9.61 TF MIF CAT
6 extracellular space GO:0005615 9.44 TF PRTN3 MIF HP HJV HFE
7 basal part of cell GO:0045178 9.33 TF SLC11A2 HFE
8 HFE-transferrin receptor complex GO:1990712 9.26 TFR2 TF HJV HFE

Biological processes related to Hemosiderosis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.97 TF SLC40A1 SLC11A2 HFE CP
2 cellular oxidant detoxification GO:0098869 9.72 HP CAT ALB
3 transferrin transport GO:0033572 9.67 TFR2 TF HFE
4 iron ion transport GO:0006826 9.62 TFR2 TF SLC11A2 CP
5 response to vitamin A GO:0033189 9.61 HAMP EPO CAT
6 cellular response to iron ion GO:0071281 9.58 TFR2 TF HFE
7 response to hyperoxia GO:0055093 9.57 EPO CAT
8 copper ion transport GO:0006825 9.56 SLC11A2 CP
9 response to iron ion GO:0010039 9.56 TFR2 SLC11A2 HFE HAMP
10 iron ion homeostasis GO:0055072 9.56 TFR2 TF SLC40A1 SLC11A2 HJV HFE
11 acute-phase response GO:0006953 9.55 TFR2 HP HFE HAMP EPO
12 positive regulation of peptide hormone secretion GO:0090277 9.54 TFR2 HFE
13 multicellular organismal iron ion homeostasis GO:0060586 9.54 SLC40A1 SLC11A2 HAMP
14 iron ion transmembrane transport GO:0034755 9.52 SLC40A1 SLC11A2
15 divalent inorganic cation transport GO:0072511 9.51 SLC40A1 SLC11A2
16 response to iron ion starvation GO:1990641 9.48 HFE HAMP
17 regulation of iron ion transport GO:0034756 9.46 TF HFE
18 cellular iron ion homeostasis GO:0006879 9.23 TFR2 TF SLC40A1 SLC11A2 HJV HFE

Molecular functions related to Hemosiderosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 copper ion binding GO:0005507 9.43 HAMP CP ALB
2 co-receptor binding GO:0039706 9.37 TFR2 HFE
3 iron ion transmembrane transporter activity GO:0005381 9.32 SLC40A1 SLC11A2
4 ferrous iron transmembrane transporter activity GO:0015093 9.16 SLC40A1 SLC11A2
5 antioxidant activity GO:0016209 9.13 HP CAT ALB
6 transferrin receptor binding GO:1990459 8.8 TF HJV HFE

Sources for Hemosiderosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....